Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

Live Webcast and Conference Call Scheduled for Thursday, March 27TH AT 5 PM

ET

TUCSON, Ariz., March 20 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Thursday, March 27, 2008, at 5:00 p.m. ET to discuss corporate updates and fourth quarter 2007 financial results.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 3, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):